Toripalimab in combination with cisplatin and paclitaxel for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (ESCC).<\/li>\n<\/ul>\n\n\n\nIn July, a positive opinion was issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the marketing authorization application (MAA) of these two indications. This approval applies to all 27 member states of the European Union, Iceland, Norway and Liechtenstein, making toripalimab the first and only drug in Europe for the treatment of NPC and the only first-line treatment for advanced or metastatic ESCC, regardless of PD-L1 status.<\/p>\n\n\n\n
NPC is a malignant tumor that occurs in the nasopharyngeal mucosal epithelium and is one of the most common types of head and neck cancers globally. According to GLOBOCAN 2022 statistics, the number of newly diagnosed NPC cases in 2022 exceeded 120,000 worldwide. Due to the location of the primary tumor, surgery is rarely an option. The latest European Society of Medical Oncology (ESMO) Guidelines recommend immunotherapy combined with chemotherapy as the first-line treatment for recurrent or metastatic NPC.<\/p>\n\n\n\n
The approval of the NPC indication is primarily based on the results from the JUPITER-02 study (a randomized, double-blind, placebo-controlled, multinational multi-center Phase III clinical study, NCT03581786). The JUPITER-02 study is the first international multi-center, double-blind, randomized Phase III clinical study in the field of immunotherapy for NPC with the largest sample size, and the world\u2019s first Phase III clinical study with preset statistical verification (Type I error control) for Overall Survival (\u201cOS\u201d) for first-line immunotherapy combined with chemotherapy for NPC compared to chemotherapy alone and demonstrated a survival benefit. The study results were presented in an oral report during the Plenary Session of the 2021 annual meeting of the American Society of Clinical Oncology (ASCO) (#LBA2) and were subsequently featured on the cover of Nature Medicine<\/em>. The results were also published in full in the Journal of the American Medical Association<\/em> (JAMA<\/em>). The results showed that, compared to chemotherapy alone, toripalimab in combination with chemotherapy reduced the risk of disease progression by 48% and the risk of death by 37%. The median progression-free survival (\u201cPFS\u201d) in the toripalimab plus chemotherapy group was prolonged by 13.2 months compared to chemotherapy alone, from 8.2 months to 21.4 months. In addition, patients treated with this combined therapy achieved a higher objective response rate (ORR), longer duration of response (DoR), and higher disease control rate (DCR), and no new safety signal was identified. Long-term survival follow-up data, presented at ASCO 2024, reported a 5-year survival rate of 52.0%.<\/p>\n\n\n\nEC is one of the most common malignant tumors in the alimentary tract. According to GLOBOCAN 2022 statistics, esophageal cancer is the 11th most commonly diagnosed cancer and the seventh leading cause of cancer death worldwide, with over 511,000 new cases and over 445,000 deaths in 2022. ESCC and esophageal adenocarcinoma are the two main histological subtypes of esophageal cancer. The ESMO Guidelines recommend PD-1 blocking antibodies combined with chemotherapy for the treatment of patients with advanced or metastatic ESCC with PD-L1 positive status.<\/p>\n\n\n\n
The approval of the ESCC indication is primarily based on the results from the JUPITER-06 study (a randomized, double-blind, placebo-controlled, multi-center Phase III clinical study, NCT03829969). The study aimed to evaluate the efficacy and safety of toripalimab in combination with paclitaxel\/cisplatin (TP) for the first-line treatment of advanced ESCC compared with placebo in combination with chemotherapy. The results were first presented in an oral session during the ESMO Congress 2021 and later published in Cancer Cell<\/em> and Journal of Clinical Oncology<\/em>, two leading international oncology journals. The results of the study showed that toripalimab in combination with chemotherapy resulted in superior PFS and OS in patients with advanced or metastatic ESCC, the median OS was prolonged by 6 months to 17 months and the risk of disease progression or death in patients was significantly reduced by 42%. Futhermore, there was significant improvement in survival benefits regardless of PD-L1 status.<\/p>\n\n\n\nProfessor Ruihua XU, Principal Investigator and President of Sun Yat-sen University Cancer Center, said, \u201cBoth NPC and EC are highly prevalent in Asia, while the development of innovative therapies for these cancer types has been slow in Europe and the Americas. The outstanding results from the JUPITER-02 and JUPITER-06 studies reflect the pioneering leadership of Chinese researchers in the diagnosis, treatment, and clinical research of NPC and EC. We hope that this \u2018Chinese Solution\u2019 will truly transform the outlook for patients around the world who have long lacked effective treatment options for these cancers, and bring them renewed hope for survival!\u201d<\/p>\n\n\n\n
Dr. Jianjun ZOU, General Manager and CEO of Junshi Biosciences, said, \u201c\u2018In China, For Global\u2019 has been a core strategic goal of Junshi Biosciences since its inception. The approval of toripalimab by the EC signifies that, following our success in China and the US, our global commercial strategy has officially expanded into Europe. It also reflects the international recognition of our research and production quality for innovative drugs. Moving forward, we will continue to collaborate with our partners on the commercialization of toripalimab in Europe, and provide high-quality, innovative therapies from China to more patients worldwide.\u201d<\/p>\n\n\n\n
Dr. Patricia Keegan, Chief Medical Officer of TopAlliance Biosciences, said, \u201cJunshi Biosciences and TopAlliance Biosciences are dedicated to producing innovative therapies that offer survival benefits to patients around the world while consistently addressing the clinical needs of local populations. This approval represents another significant milestone in our entry into the global market. In addition to toripalimab, we have several promising indications and drugs under development internationally. We believe that our commitment to providing patients with more effective treatment options will continually motivate us toward becoming a leading international innovative enterprise.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"
The European Commission has approved toripalimab for the 1st-line treatment of advanced NPC and ESCC<\/p>\n","protected":false},"author":4,"featured_media":2926,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[22],"tags":[],"class_list":["post-2966","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"yoast_head":"\n
Junshi Biosciences Announces European Commission Approval for Marketing of Toripalimab - \u541b\u5b9e\u751f\u7269<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.junshipharma.com\/en\/\u541b\u5b9e\u751f\u7269\u7279\u745e\u666e\u5229\u5355\u6297\u83b7\u5f97\u6b27\u76df\u59d4\u5458\u4f1a\u6279\u51c6\u4e0a\u5e02\uff0c\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Junshi Biosciences Announces European Commission Approval for Marketing of Toripalimab - \u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"og:description\" content=\"The European Commission has approved toripalimab for the 1st-line treatment of advanced NPC and ESCC\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.junshipharma.com\/en\/\u541b\u5b9e\u751f\u7269\u7279\u745e\u666e\u5229\u5355\u6297\u83b7\u5f97\u6b27\u76df\u59d4\u5458\u4f1a\u6279\u51c6\u4e0a\u5e02\uff0c\/\" \/>\n<meta property=\"og:site_name\" content=\"\u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"article:published_time\" content=\"2024-09-25T07:16:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-29T08:32:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.junshipharma.com\/wp-content\/uploads\/2024\/10\/\u5c01\u9762.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u6797, \u4f9d\u9896\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u6797, \u4f9d\u9896\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.junshipharma.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%8e%b7%e5%be%97%e6%ac%a7%e7%9b%9f%e5%a7%94%e5%91%98%e4%bc%9a%e6%89%b9%e5%87%86%e4%b8%8a%e5%b8%82%ef%bc%8c\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.junshipharma.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%8e%b7%e5%be%97%e6%ac%a7%e7%9b%9f%e5%a7%94%e5%91%98%e4%bc%9a%e6%89%b9%e5%87%86%e4%b8%8a%e5%b8%82%ef%bc%8c\/\"},\"author\":{\"name\":\"\u6797, \u4f9d\u9896\",\"@id\":\"https:\/\/www.junshipharma.com\/#\/schema\/person\/1cc6a200ecdd3f0fb5f157d2c2f048c2\"},\"headline\":\"Junshi Biosciences Announces European Commission Approval for Marketing of Toripalimab\",\"datePublished\":\"2024-09-25T07:16:42+00:00\",\"dateModified\":\"2024-11-29T08:32:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.junshipharma.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%8e%b7%e5%be%97%e6%ac%a7%e7%9b%9f%e5%a7%94%e5%91%98%e4%bc%9a%e6%89%b9%e5%87%86%e4%b8%8a%e5%b8%82%ef%bc%8c\/\"},\"wordCount\":1021,\"publisher\":{\"@id\":\"https:\/\/www.junshipharma.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.junshipharma.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%8e%b7%e5%be%97%e6%ac%a7%e7%9b%9f%e5%a7%94%e5%91%98%e4%bc%9a%e6%89%b9%e5%87%86%e4%b8%8a%e5%b8%82%ef%bc%8c\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.junshipharma.com\/wp-content\/uploads\/2024\/10\/\u5c01\u9762.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.junshipharma.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%8e%b7%e5%be%97%e6%ac%a7%e7%9b%9f%e5%a7%94%e5%91%98%e4%bc%9a%e6%89%b9%e5%87%86%e4%b8%8a%e5%b8%82%ef%bc%8c\/\",\"url\":\"https:\/\/www.junshipharma.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%8e%b7%e5%be%97%e6%ac%a7%e7%9b%9f%e5%a7%94%e5%91%98%e4%bc%9a%e6%89%b9%e5%87%86%e4%b8%8a%e5%b8%82%ef%bc%8c\/\",\"name\":\"Junshi Biosciences Announces European Commission Approval for Marketing of Toripalimab - \u541b\u5b9e\u751f\u7269\",\"isPartOf\":{\"@id\":\"https:\/\/www.junshipharma.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.junshipharma.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%8e%b7%e5%be%97%e6%ac%a7%e7%9b%9f%e5%a7%94%e5%91%98%e4%bc%9a%e6%89%b9%e5%87%86%e4%b8%8a%e5%b8%82%ef%bc%8c\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.junshipharma.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%8e%b7%e5%be%97%e6%ac%a7%e7%9b%9f%e5%a7%94%e5%91%98%e4%bc%9a%e6%89%b9%e5%87%86%e4%b8%8a%e5%b8%82%ef%bc%8c\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.junshipharma.com\/wp-content\/uploads\/2024\/10\/\u5c01\u9762.jpg\",\"datePublished\":\"2024-09-25T07:16:42+00:00\",\"dateModified\":\"2024-11-29T08:32:17+00:00\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.junshipharma.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%8e%b7%e5%be%97%e6%ac%a7%e7%9b%9f%e5%a7%94%e5%91%98%e4%bc%9a%e6%89%b9%e5%87%86%e4%b8%8a%e5%b8%82%ef%bc%8c\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.junshipharma.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%8e%b7%e5%be%97%e6%ac%a7%e7%9b%9f%e5%a7%94%e5%91%98%e4%bc%9a%e6%89%b9%e5%87%86%e4%b8%8a%e5%b8%82%ef%bc%8c\/#primaryimage\",\"url\":\"https:\/\/www.junshipharma.com\/wp-content\/uploads\/2024\/10\/\u5c01\u9762.jpg\",\"contentUrl\":\"https:\/\/www.junshipharma.com\/wp-content\/uploads\/2024\/10\/\u5c01\u9762.jpg\",\"width\":1200,\"height\":800},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.junshipharma.com\/#website\",\"url\":\"https:\/\/www.junshipharma.com\/\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"description\":\"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002\",\"publisher\":{\"@id\":\"https:\/\/www.junshipharma.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.junshipharma.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.junshipharma.com\/#organization\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"url\":\"https:\/\/www.junshipharma.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.junshipharma.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.junshipharma.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"contentUrl\":\"https:\/\/www.junshipharma.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"width\":2147,\"height\":795,\"caption\":\"\u541b\u5b9e\u751f\u7269\"},\"image\":{\"@id\":\"https:\/\/www.junshipharma.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.junshipharma.com\/#\/schema\/person\/1cc6a200ecdd3f0fb5f157d2c2f048c2\",\"name\":\"\u6797, \u4f9d\u9896\",\"url\":\"https:\/\/www.junshipharma.com\/en\/author\/yiying_lin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Junshi Biosciences Announces European Commission Approval for Marketing of Toripalimab - \u541b\u5b9e\u751f\u7269","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.junshipharma.com\/en\/\u541b\u5b9e\u751f\u7269\u7279\u745e\u666e\u5229\u5355\u6297\u83b7\u5f97\u6b27\u76df\u59d4\u5458\u4f1a\u6279\u51c6\u4e0a\u5e02\uff0c\/","og_locale":"en_US","og_type":"article","og_title":"Junshi Biosciences Announces European Commission Approval for Marketing of Toripalimab - \u541b\u5b9e\u751f\u7269","og_description":"The European Commission has approved toripalimab for the 1st-line treatment of advanced NPC and ESCC","og_url":"https:\/\/www.junshipharma.com\/en\/\u541b\u5b9e\u751f\u7269\u7279\u745e\u666e\u5229\u5355\u6297\u83b7\u5f97\u6b27\u76df\u59d4\u5458\u4f1a\u6279\u51c6\u4e0a\u5e02\uff0c\/","og_site_name":"\u541b\u5b9e\u751f\u7269","article_published_time":"2024-09-25T07:16:42+00:00","article_modified_time":"2024-11-29T08:32:17+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/www.junshipharma.com\/wp-content\/uploads\/2024\/10\/\u5c01\u9762.jpg","type":"image\/jpeg"}],"author":"\u6797, \u4f9d\u9896","twitter_card":"summary_large_image","twitter_misc":{"Written by":"\u6797, \u4f9d\u9896","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.junshipharma.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%8e%b7%e5%be%97%e6%ac%a7%e7%9b%9f%e5%a7%94%e5%91%98%e4%bc%9a%e6%89%b9%e5%87%86%e4%b8%8a%e5%b8%82%ef%bc%8c\/#article","isPartOf":{"@id":"https:\/\/www.junshipharma.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%8e%b7%e5%be%97%e6%ac%a7%e7%9b%9f%e5%a7%94%e5%91%98%e4%bc%9a%e6%89%b9%e5%87%86%e4%b8%8a%e5%b8%82%ef%bc%8c\/"},"author":{"name":"\u6797, \u4f9d\u9896","@id":"https:\/\/www.junshipharma.com\/#\/schema\/person\/1cc6a200ecdd3f0fb5f157d2c2f048c2"},"headline":"Junshi Biosciences Announces European Commission Approval for Marketing of Toripalimab","datePublished":"2024-09-25T07:16:42+00:00","dateModified":"2024-11-29T08:32:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.junshipharma.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%8e%b7%e5%be%97%e6%ac%a7%e7%9b%9f%e5%a7%94%e5%91%98%e4%bc%9a%e6%89%b9%e5%87%86%e4%b8%8a%e5%b8%82%ef%bc%8c\/"},"wordCount":1021,"publisher":{"@id":"https:\/\/www.junshipharma.com\/#organization"},"image":{"@id":"https:\/\/www.junshipharma.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%8e%b7%e5%be%97%e6%ac%a7%e7%9b%9f%e5%a7%94%e5%91%98%e4%bc%9a%e6%89%b9%e5%87%86%e4%b8%8a%e5%b8%82%ef%bc%8c\/#primaryimage"},"thumbnailUrl":"https:\/\/www.junshipharma.com\/wp-content\/uploads\/2024\/10\/\u5c01\u9762.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.junshipharma.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%8e%b7%e5%be%97%e6%ac%a7%e7%9b%9f%e5%a7%94%e5%91%98%e4%bc%9a%e6%89%b9%e5%87%86%e4%b8%8a%e5%b8%82%ef%bc%8c\/","url":"https:\/\/www.junshipharma.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%8e%b7%e5%be%97%e6%ac%a7%e7%9b%9f%e5%a7%94%e5%91%98%e4%bc%9a%e6%89%b9%e5%87%86%e4%b8%8a%e5%b8%82%ef%bc%8c\/","name":"Junshi Biosciences Announces European Commission Approval for Marketing of Toripalimab - \u541b\u5b9e\u751f\u7269","isPartOf":{"@id":"https:\/\/www.junshipharma.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.junshipharma.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%8e%b7%e5%be%97%e6%ac%a7%e7%9b%9f%e5%a7%94%e5%91%98%e4%bc%9a%e6%89%b9%e5%87%86%e4%b8%8a%e5%b8%82%ef%bc%8c\/#primaryimage"},"image":{"@id":"https:\/\/www.junshipharma.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%8e%b7%e5%be%97%e6%ac%a7%e7%9b%9f%e5%a7%94%e5%91%98%e4%bc%9a%e6%89%b9%e5%87%86%e4%b8%8a%e5%b8%82%ef%bc%8c\/#primaryimage"},"thumbnailUrl":"https:\/\/www.junshipharma.com\/wp-content\/uploads\/2024\/10\/\u5c01\u9762.jpg","datePublished":"2024-09-25T07:16:42+00:00","dateModified":"2024-11-29T08:32:17+00:00","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.junshipharma.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%8e%b7%e5%be%97%e6%ac%a7%e7%9b%9f%e5%a7%94%e5%91%98%e4%bc%9a%e6%89%b9%e5%87%86%e4%b8%8a%e5%b8%82%ef%bc%8c\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.junshipharma.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%8e%b7%e5%be%97%e6%ac%a7%e7%9b%9f%e5%a7%94%e5%91%98%e4%bc%9a%e6%89%b9%e5%87%86%e4%b8%8a%e5%b8%82%ef%bc%8c\/#primaryimage","url":"https:\/\/www.junshipharma.com\/wp-content\/uploads\/2024\/10\/\u5c01\u9762.jpg","contentUrl":"https:\/\/www.junshipharma.com\/wp-content\/uploads\/2024\/10\/\u5c01\u9762.jpg","width":1200,"height":800},{"@type":"WebSite","@id":"https:\/\/www.junshipharma.com\/#website","url":"https:\/\/www.junshipharma.com\/","name":"\u541b\u5b9e\u751f\u7269","description":"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002","publisher":{"@id":"https:\/\/www.junshipharma.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.junshipharma.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.junshipharma.com\/#organization","name":"\u541b\u5b9e\u751f\u7269","url":"https:\/\/www.junshipharma.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.junshipharma.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.junshipharma.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","contentUrl":"https:\/\/www.junshipharma.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","width":2147,"height":795,"caption":"\u541b\u5b9e\u751f\u7269"},"image":{"@id":"https:\/\/www.junshipharma.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.junshipharma.com\/#\/schema\/person\/1cc6a200ecdd3f0fb5f157d2c2f048c2","name":"\u6797, \u4f9d\u9896","url":"https:\/\/www.junshipharma.com\/en\/author\/yiying_lin\/"}]}},"_links":{"self":[{"href":"https:\/\/www.junshipharma.com\/en\/wp-json\/wp\/v2\/posts\/2966"}],"collection":[{"href":"https:\/\/www.junshipharma.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.junshipharma.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.junshipharma.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.junshipharma.com\/en\/wp-json\/wp\/v2\/comments?post=2966"}],"version-history":[{"count":2,"href":"https:\/\/www.junshipharma.com\/en\/wp-json\/wp\/v2\/posts\/2966\/revisions"}],"predecessor-version":[{"id":3184,"href":"https:\/\/www.junshipharma.com\/en\/wp-json\/wp\/v2\/posts\/2966\/revisions\/3184"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.junshipharma.com\/en\/wp-json\/wp\/v2\/media\/2926"}],"wp:attachment":[{"href":"https:\/\/www.junshipharma.com\/en\/wp-json\/wp\/v2\/media?parent=2966"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.junshipharma.com\/en\/wp-json\/wp\/v2\/categories?post=2966"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.junshipharma.com\/en\/wp-json\/wp\/v2\/tags?post=2966"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}